These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1745 related articles for article (PubMed ID: 29061175)

  • 1. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
    Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M
    J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis.
    Li S; Lyu N; Han X; Li J; Lai J; He M; Deng H; Shi M; Wang H; Zhao M
    J Vasc Interv Radiol; 2021 Sep; 32(9):1267-1276.e1. PubMed ID: 34166806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients.
    Gao S; Zhang PJ; Guo JH; Chen H; Xu HF; Liu P; Yang RJ; Zhu X
    World J Gastroenterol; 2015 Sep; 21(36):10443-52. PubMed ID: 26420971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
    Li JH; Xie XY; Zhang L; Le F; Ge NL; Li LX; Gan YH; Chen Y; Zhang JB; Xue TC; Chen RX; Xia JL; Zhang BH; Ye SL; Wang YH; Ren ZG
    World J Gastroenterol; 2015 Apr; 21(13):3970-7. PubMed ID: 25852283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.
    Kim HY; Kim JD; Bae SH; Park JY; Han KH; Woo HY; Choi JY; Yoon SK; Jang BK; Hwang JS; Kim SG; Kim YS; Seo YS; Yim HJ; Um SH;
    Korean J Hepatol; 2010 Dec; 16(4):355-61. PubMed ID: 21415578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials.
    Huang Y; Zhang L; He M; Lai Z; Bu X; Wen D; Li Q; Xu L; Wei W; Zhang Y; Zhou Z; Chen M; Guo R; Shi M; Kan A
    Technol Cancer Res Treat; 2022; 21():15330338221117389. PubMed ID: 36529949
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma.
    Lin ZP; Hu XL; Chen D; Huang DB; Zou XG; Zhong H; Xu SX; Chen Y; Li XQ; Zhang J
    World J Gastroenterol; 2024 May; 30(17):2321-2331. PubMed ID: 38813052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study.
    Huang Z; Chen T; Li W; He W; Liu S; Wu Z; Li B; Yuan Y; Qiu J
    Int Immunopharmacol; 2024 Sep; 139():112711. PubMed ID: 39029233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential vs. concurrent systemic therapies in combination with FOLFOX-HAIC for locally advanced hepatocellular carcinoma: a single-center, real-world cohort study.
    Sun L; Hu Z; Xie W; Yang Z; Zeng H; Zhang Y; Chen M; Hu D; Zhou Z; Pan Y
    BMC Cancer; 2024 Sep; 24(1):1168. PubMed ID: 39300392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.
    Guo JH; Liu SX; Gao S; Kou FX; Zhang X; Wu D; Li XT; Chen H; Wang XD; Liu P; Zhang PJ; Xu HF; Cao G; Zhu LZ; Yang RJ; Zhu X
    World J Gastroenterol; 2020 Jul; 26(27):3975-3988. PubMed ID: 32774071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of hepatic arterial infusion chemotherapy in patients with primary liver cancer with portal vein tumor thrombosis: a comparative analysis of different perfusion chemotherapeutic regimens.
    Tu X; Zhang W; Li S; He Q; Li Y
    Eur J Med Res; 2024 Sep; 29(1):465. PubMed ID: 39294739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.
    Chen Y; Jia L; Li Y; Cui W; Wang J; Zhang C; Bian C; Wang Z; Lin D; Luo T
    Ann Surg Oncol; 2024 Nov; 31(12):7860-7869. PubMed ID: 39090499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
    He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
    Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy.
    Li M; Liao J; Wang L; Lv T; Sun Q; Xu Y; Guo Z; Quan M; Qin H; Yu H; Zhang K; Xing W; Yu H
    Front Immunol; 2024; 15():1303259. PubMed ID: 38660298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    He M; Li Q; Zou R; Shen J; Fang W; Tan G; Zhou Y; Wu X; Xu L; Wei W; Le Y; Zhou Z; Zhao M; Guo Y; Guo R; Chen M; Shi M
    JAMA Oncol; 2019 Jul; 5(7):953-960. PubMed ID: 31070690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.
    Tsai WL; Lai KH; Liang HL; Hsu PI; Chan HH; Chen WC; Yu HC; Tsay FW; Wang HM; Tsai HC; Cheng JS
    PLoS One; 2014; 9(5):e92784. PubMed ID: 24824520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.